• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sqz Biotechnologies Company (NY: SQZ )

N/A UNCHANGED
Last Price Updated: 5:00 PM EDT, Jul 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sqz Biotechnologies Company

< Previous 1 2 3 Next >
Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider
May 06, 2024
From GENENTA SCIENCE SPA
Via GlobeNewswire
SQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock Split
June 15, 2023
From SQZ Biotechnologies Company
Via Business Wire
SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates
May 10, 2023
From SQZ Biotechnologies Company
Via Business Wire
SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial
March 22, 2023
From SQZ Biotechnologies Company
Via Business Wire
SQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio Updates
March 22, 2023
From SQZ Biotechnologies Company
Via Business Wire
NYSE:SQZ Investor Alert: Investigation over Potential Wrongdoing at SQZ Biotechnologies Company
February 27, 2023
San Diego, CA -- (SBWIRE) -- 02/27/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at SQZ Biotechnologies Company. 
Via SBWire
SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange
January 18, 2023
From SQZ Biotechnologies
Via Business Wire
NYSE:SQZ Investor Notice: Investigation over Possible Securities Laws Violations by SQZ Biotechnologies Company
December 13, 2022
San Diego, CA -- (SBWIRE) -- 12/13/2022 -- SQZ Biotechnologies Company is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology Congress
December 06, 2022
From SQZ Biotechnologies Company
Via Business Wire
SQZ Biotechnologies Announces Strategic Prioritization of SQZ® Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive Officer
November 30, 2022
From SQZ Biotechnologies
Via Business Wire
SQZ Biotechnologies Presents Cell Squeeze® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual Meeting
November 10, 2022
From SQZ Biotechnologies
Via Business Wire
SQZ Biotechnologies Reports Third Quarter 2022 Financial Results and Recent Portfolio Updates
November 09, 2022
From SQZ Biotechnologies
Via Business Wire
SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform’s Potential as an Effective Red Blood Cell-Derived Immunotherapy
October 03, 2022
From SQZ Biotechnologies Company
Via Business Wire
SQZ Biotechnologies Presents Preclinical SQZ® TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell Therapies
September 12, 2022
From SQZ Biotechnologies Company
Via Business Wire
SQZ Biotechnologies to Present at Upcoming Investor Conferences
September 07, 2022
From SQZ Biotechnologies Company
Via Business Wire
SQZ Biotechnologies Announces Leadership Transition
September 06, 2022
From SQZ Biotechnologies Company
Via Business Wire
SQZ Biotechnologies Reports Second Quarter 2022 Financial Results and Recent Portfolio Updates
August 04, 2022
From SQZ Biotechnologies
Via Business Wire
SQZ Biotechnologies and Collaborators Publish Technology Review on SQZ® APCs and Effective CD8 T Cell Activation
July 12, 2022
From SQZ Biotechnologies Company
Via Business Wire
SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer
July 11, 2022
From SQZ Biotechnologies
Via Business Wire
SQZ Biotechnologies Presents Celiac Disease Tolerizing Antigen Carrier Preclinical Data at 2022 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
June 21, 2022
From SQZ Biotechnologies Company
Via Business Wire
SQZ Biotechnologies Announces Generation of Dopaminergic Neurons from Human Pluripotent Stem Cells Through Single-Step Delivery of Six Cell-Fate Encoding RNAs
June 16, 2022
From SQZ Biotechnologies Company
Via Business Wire
SQZ Biotechnologies to Present at Jefferies Healthcare Conference
June 01, 2022
From SQZ Biotechnologies
Via Business Wire
SQZ Biotechnologies Appoints Marshelle Smith Warren, M.D., as Chief Medical Officer
May 31, 2022
From SQZ Biotechnologies
Via Business Wire
SQZ Biotechnologies Announces Integrated Point-of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process
May 18, 2022
From SQZ Biotechnologies
Via Business Wire
SQZ Biotechnologies Reports First Quarter 2022 Financial Results and Recent Portfolio Updates
May 10, 2022
From SQZ Biotechnologies
Via Business Wire
SQZ Biotechnologies to Host Live & Virtual R&D Investor Event on May 19, 2022
May 05, 2022
From SQZ Biotechnologies
Via Business Wire
SQZ Biotechnologies Announces First Data Presentation on Non-Clinical Studies of Point-of-Care Manufacturing System and Collaboration with STEMCELL Technologies on Research-Use-Only System to Fuel Preclinical Research
May 05, 2022
From SQZ Biotechnologies
Via Business Wire
SQZ Biotechnologies to Present at Upcoming Investor Conferences
May 03, 2022
From SQZ Biotechnologies
Via Business Wire
SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors
April 27, 2022
From SQZ Biotechnologies
Via Business Wire
SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo
April 11, 2022
From SQZ Biotechnologies
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap